Journal Mobile Options
Table of Contents
Vol. 58, No. 4, 2012
Issue release date: November 2012
Section title: Clinical Study
Chemotherapy 2012;58:257–263
(DOI:10.1159/000341274)

A Phase I Clinical Trial of Irinotecan and Carboplatin in Patients with Extensive Stage Small Cell Lung Cancer

Crabb S.J. · Bradbury J. · Nolan L. · Selman D. · Muthuramalingam S.R. · Cave J. · Johnson P.W.M. · Ottensmeier C.
aDepartment of Medical Oncology, University Hospital Southampton NHS Foundation Trust, and bCancer Research UK Centre, University of Southampton Faculty of Medicine, Southampton General Hospital, Southampton, and cDepartment of Medical Oncology, Portsmouth Hospitals NHS Trust, Queen Alexandra Hospital, Portsmouth, UK

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Clinical Study

Received: 12/2/2011 9:46:40 AM
Accepted: 6/23/2012
Published online: 8/15/2012

Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 4

ISSN: 0009-3157 (Print)
eISSN: 1421-9794 (Online)

For additional information: http://www.karger.com/CHE

Abstract

Background: Treatment options for small cell lung cancer (SCLC) remain inadequate. Irinotecan has been tested in various combinations with platinum agents but the optimal regimen remains uncertain. We undertook a phase I trial to optimise the dose intensity of a 3-weekly irinotecan/carboplatin combination. Methods: Twenty patients with extensive stage SCLC received intravenous carboplatin at an area under the curve (AUC) of 5 on day 1, and irinotecan in 40–70 mg/m2 dose levels on days 1 and 8, every 21 days, for up to 6 cycles. Results: Dose-limiting toxicity occurred in 1 patient at the 50 mg/m2 irinotecan level (grade 3 diarrhoea) and in 2 patients at 70 mg/m2 (grade 5 neutropenic sepsis; combined grade 4 febrile neutropenia, grade 4 diarrhoea and grade 3 thrombosis). Toxicity patterns were consistent with the expected profile for this combination. The objective response rate was 75% and the median survival was 9.3 months (95% confidence interval 7.5–11.2). Conclusion: Irinotecan 60 mg/m2 on days 1 and 8 combined with carboplatin AUC 5 every 21 days is recommended for phase II evaluation. This regimen has clinical activity, acceptable toxicity and greater dose intensity over those currently tested in phase III trials.


  

Author Contacts

Dr. Simon J. Crabb
Cancer Research UK Centre, University of Southampton
Faculty of Medicine, Mailpoint 824, Southampton General Hospital
Tremona Road, Southampton SO16 6YD (UK)
Tel. +44 23 8079 5170, E-Mail S.J.Crabb@southampton.ac.uk

  

Article Information

Received: December 2, 2011
Accepted after revision: June 23, 2012
Published online: August 15, 2012
Number of Print Pages : 7
Number of Figures : 0, Number of Tables : 4, Number of References : 16

  

Publication Details

Chemotherapy (International Journal of Experimental and Clinical Chemotherapy)

Vol. 58, No. 4, Year 2012 (Cover Date: November 2012)

Journal Editor: Sörgel F. (Nürnberg-Heroldsberg)
ISSN: 0009-3157 (Print), eISSN: 1421-9794 (Online)

For additional information: http://www.karger.com/CHE


Article / Publication Details

First-Page Preview
Abstract of Clinical Study

Received: 12/2/2011 9:46:40 AM
Accepted: 6/23/2012
Published online: 8/15/2012

Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 4

ISSN: 0009-3157 (Print)
eISSN: 1421-9794 (Online)

For additional information: http://www.karger.com/CHE


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.